Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder

Original research
by
Lier, Audun J. et al

Release Date

2022

Geography

USA

Language of Resource

English

Full Text Available

No

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

Opioid use disorder (OUD) and injection drug use (IDU) place justice-involved individuals at increased risk for acquiring or transmitting HIV or hepatitis C virus (HCV). Methadone and buprenorphine have been associated with reduced opioid IDU; however, the effect of extended-release naltrexone (XR-NTX) on this behavior is incompletely studied.

Findings/Key points

Injection opioid use was low during incarceration and remained low postrelease in this justice-involved population. Retention on XR-NTX was associated with reduced intravenous opioid use, which has important implications for reducing transmission of HIV and HCV.

Design/methods

Double-blind placebo-controlled trial (n=88)

Keywords

Justice system/law enforcement
Substitution/OAT